Pegmolesatide is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is The First Affiliated Hospital of Dalian Medical University (1). The most-studied condition is Renal Anemia in Non-dialysis Chronic Kidney Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Use of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switching to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HIF-PHI
NCT06946394 · ClinicalTrials.gov ↗ · Renal Anemia in Non-dialysis Chronic Kidney Disease
|
Phase 4 | Recruiting | The First Affiliated Hospital of Dalian Medical University | China |
|
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792 · ClinicalTrials.gov ↗ · Renal Anemia of Chronic Kidney Disease
|
Not applicable | Recruiting | Guangdong Provincial People's Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| The First Affiliated Hospital of Dalian Medical University | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Pegmolesatide (also registered as EPO-018B) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The First Affiliated Hospital of Dalian Medical University (1) and Guangdong Provincial People's Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pegmolesatide works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pegmolesatide works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pegmolesatide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.